# A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)

> **NCT02849951** · PHASE3 · TERMINATED · sponsor: **Prometheus Laboratories** · enrollment: 25 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** LT-02
- **DRUG:** LT-02 Placebo

## Key facts

- **NCT ID:** NCT02849951
- **Lead sponsor:** Prometheus Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07
- **Primary completion:** 2019-03
- **Final completion:** 2019-08
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** LT-02 did not appear to help induce remission of UC
- **Last updated:** 2017-06-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02849951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02849951, "A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02849951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*